EUCTR2020-005229-95-NL进行中（未招募）1 期
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Disease (Globoid Cell Leukodystrophy) (GALax-C) - Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects with Early Infantile Krab
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. =1 month and <9 months of age at enrollment, either presymptomatic or symptomatic with first symptoms of Krabbe disease at =6 months of age
- •2. Leukocyte GALC activity below the lower limit of normal (LLN) of the testing central laboratory (e.g., <0.30 nmol/hour/mg protein )
- •3. Whole blood psychosine >10 nM
- •4. Biallelic pathogenic GALC gene variants associated with early infantile Krabbe disease or variants classified as likely pathogenic (testing must be done at a Clinical Laboratory Improvement Amendments [CLIA] or CLIA-equivalent laboratory certified per local standard. If the GALC gene analysis is performed in the UK or the European Union (EU) a Conformité Européenne (CE) marked test will be used). See also Appendix 2, Classification of GALC Gene Variants.
- •Note: Subjects without documentation of two pathogenic or likely pathogenic GALC variants but who meet all other inclusion criteria, including low GALC activity and high psychosine level, may be considered eligible for the study. In this case the totality of the available data, including relevant family history, must be consistent with a diagnosis of early infantile Krabbe disease.
- •5. Parents or the subject’s legally authorized representative (LAR) provide(s) written informed consent prior to any study-related procedures, including screening evaluations
- •6. Symptomatic subjects must exhibit a minimum level of neurological and developmental function that indicates they have the potential to benefit from treatment, at least with slowing or stabilization of their disease. In particular, the subject must demonstrate the following clinical features (when age-appropriate):
- •a. Thrusting of legs in play (Bayley motor scale, gross motor subset, item 1)
- •b. Lifting of head (Bayley motor scale, gross motor subset, item 3)
- •c. Eyes follow moving person (Bayley motor scale, fine motor subset, item 2)
- •d. Smiles in response to speaker’s attention (Bayley language scale, expressive, item 2)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 28
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any clinically significant neurocognitive deficit not attributable to KD
- •2. An acute illness requiring hospitalization within 30 days of enrollment, that, in the opinion of the Investigator, would interfere with the evaluation of the investigational product or interpretation of subject safety or study results.
- •3. History of chronic ventilation assisted respiratory support (= use of more than 12 h/day of BiPap, Cpap or ventilator) or a need for tracheostomy as a result of their disease. Note: This does not exclude subjects who use respiratory vests.
- •4. Intractable seizure/uncontrolled epilepsy defined as having had an episode of status epilepticus, or seizures requiring hospitalization
- •a. This does not exclude subjects who have a history of staring spells that have not been associated with EEG findings
- •5. Family history of seizure disorders/epilepsy of infantile or childhood onset, other than febrile seizures
- •a. This does not exclude subjects with a family history of KD
- •6. Any contraindication to ICM admin procedure, including contraindications to fluoroscopic imaging, intrathecal contrast and anesthesia, or any condition that would increase the risk of adverse outcomes from the ICM procedure, including but not limited to the presence of space occupying lesion causing mass effect or signs of increased intracranial pressure, non-communicating hydrocephalus, space-occupying lesion in the posterior fossa or foramen magnum, aberrant vascular anatomy such as a large midline posterior inferior cerebellar artery, venous anomaly such as a large midline cerebellar vein or occipital sinus, congenital anatomical abnormalities such as Chiari malformation.
- •7. Any contraindication to MRI or LP
- •8. Prior gene therapy.
- •9. Enrollment in any other clinical study with an investigational product within 4 weeks prior to Screening or within 5 half-lives of the investigational product used in that clinical study, whichever is longer
- •10. Prior HSCT
- •11. Receipt of a vaccine within 14 days prior to and up to 30 days after dosing
- •12. eGFR <60 mL/min/1.73 m2 based on creatinine, determined using the Bedside Schwartz equation
- •13. Hematological abnormalities:
- •a. Coagulopathy (INR > 1.5 or aPTT > 40 seconds)
- •b. Thrombocytopenia (platelet count < 100,000 per µL)
- •c. WBC <5.5 x 10^3 cells/µL
- •d. Hemoglobin <10 g/dL.
- •14. AST or ALT >3 x ULN or total bilirubin >1.5 x ULN.
- •15. Abnormal respiratory function:
- •a. Required suctioning in the absence of upper respiratory tract infection
- •b. Hypoxemia (oxygen [O2] saturation awake < 96% or O2 saturation asleep < 96%, without ventilation support) as assessed during screening. Ventilatory support defined as dependence on supplemental O2 or use of a ventilator or BiPap or Cpap machine.
- •16. Poor peripheral perfusion or temperature instability in the absence of intercurrent illness
- •17. Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from ICM injection, anesthesia,
- •fluoroscopy, LP, and/or MRI (Temp > 38°C, oxygen saturation < 95% on room air or baseline oxygen requirement, heart rate or respiratory rate
- •abnormal for age of the subject, abnormal blood pressure for age, evidence of infection)
- •18. Any condition (eg history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or
研究者
相似试验
尚未招募
2 期
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Disease (Globoid Cell Leukodystrophy) (GALax-C)NL-OMON51988Passage Bio, Inc.3
进行中（未招募）
1 期
A Phase 1b/2 Trial of SRA737 in Combination with Niraparib in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)Histologically or cytologically confirmed adenocarcinoma of the prostateMedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2017-004927-56-GBSierra Oncology, Inc.70
进行中（未招募）
不适用
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects with Mucopolysaccharidosis IVA (Morquio Syndrome)EUCTR2008-007365-23-GBBioMarin Pharmaceutical Inc.
进行中（未招募）
1 期
A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, effectiveness and how the body deals with the drug in patients with multiple myeloma that reoccurs or is resistant to medicines patients have already tried.RELAPSED AND REFRACTORY MULTIPLE MYELOMAMedDRA version: 21.1Level: LLTClassification code 10067095Term: Multiple myeloma progressionSystem Organ Class: 100000004864MedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851EUCTR2016-000860-40-GBCelgene Corporation303
进行中（未招募）
1 期
An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)Acute Myelogenous Leukemia (AML)MedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-003285-33-GBAkinion Pharmaceuticals AB25